751 related articles for article (PubMed ID: 26177074)
1. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
[TBL] [Abstract][Full Text] [Related]
2. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
7. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
Wedzicha JA; Dahl R; Buhl R; Schubert-Tennigkeit A; Chen H; D'Andrea P; Fogel R; Banerji D
Respir Med; 2014 Oct; 108(10):1498-507. PubMed ID: 25135743
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies.
Ohar JA; Sharma S; Goodin T; Bowling A; Price B; Ozol-Godfrey A; Sanjar S
COPD; 2019 Apr; 16(2):133-139. PubMed ID: 31242792
[TBL] [Abstract][Full Text] [Related]
9. Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies.
Tashkin DP; Goodin T; Bowling A; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Respir Med; 2019 Aug; 155():113-120. PubMed ID: 31344660
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
11. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
Kerstjens HA; Deslée G; Dahl R; Donohue JF; Young D; Lawrence D; Kornmann O
Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
13. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Rossi A; Zanardi E; Poletti V; Cazzola M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
16. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
[TBL] [Abstract][Full Text] [Related]
17. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
[TBL] [Abstract][Full Text] [Related]
18. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
Frampton JE
Drugs; 2014 Mar; 74(4):465-88. PubMed ID: 24604791
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
